Insulet Launches Omnipod 5 with Expanded Sensor Integrations in UK and Netherlands

Insulet Corporation, a leading company in tubeless insulin pump technology under the Omnipod® brand, has announced the full availability of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in the U.K. and the Netherlands. This device, designed for individuals aged two and older with type 1 diabetes, is notable for its compatibility with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors. Omnipod 5 is distinguished as the first and only tubeless automated insulin delivery (AID) system that integrates with both of these leading CGM brands.

The strategic expansion aims to provide more people with diabetes the option to use tubeless, automated insulin delivery without the need to switch their existing CGM sensor brand. Patrick Crannell, Insulet's Senior Vice President and International General Manager, emphasized the significance of this development, stating that the updated compatibility with both CGM sensors is expected to greatly benefit thousands of individuals by offering them greater freedom in managing their diabetes.

Omnipod 5 has been designed to offer proactive glucose control and is customer-centric, ensuring ease of use. Clinical results have shown that it helps users achieve lower A1c levels and improved time in range while maintaining minimal time in hypoglycemia. This makes the system not only effective but also safe for users.

An 18-year-old student from the Netherlands, Dion Screever, shared his positive experience with Omnipod 5. He reported significant improvements in his blood sugar levels and less effort required on his part to manage his condition since starting on Omnipod 5. This feedback underscores the potential of Omnipod 5 to transform the lives of those living with type 1 diabetes by providing them with more autonomy and ease in managing their condition.

The integration of multiple sensors, including the Dexcom G6 and Abbott FreeStyle Libre 2 Plus, provides prescribers with more flexibility when recommending sensors to their patients. During the setup process, customers can choose the sensor they prefer to connect to Omnipod 5, making the transition to AID therapy smoother and more personalized.

Professor Partha S. Kar, a consultant endocrinologist and Technology Lead for Type 1 Diabetes at NHS England, highlighted the importance of the recent integration of Omnipod 5 with the FreeStyle Libre 2 Plus sensor. He noted that this advancement will enable more individuals in the U.K. and the Netherlands to experience the benefits of automated insulin delivery, marking a significant step forward in simplifying diabetes management for many.

Insulet Corporation, headquartered in Massachusetts, is dedicated to simplifying life for people with diabetes through its innovative Omnipod product platform. The Omnipod Insulin Management System offers a unique alternative to traditional insulin delivery methods with its simple, wearable design. The disposable Pod provides continuous insulin delivery for up to three days without the need for needles. The Omnipod 5 Automated Insulin Delivery System integrates with a continuous glucose monitor to manage blood sugar levels without the need for multiple daily injections or fingersticks and can be controlled by a compatible smartphone or the Omnipod 5 Controller.

Insulet is also exploring the use of its Omnipod technology platform for the delivery of other non-insulin subcutaneous drugs, expanding its applications across various therapeutic areas. This further demonstrates the versatility and adaptability of their technology in addressing different medical needs.